Cerity Partners
IKT icon

Cerity Partners’s Inhibikase Therapeutics IKT Stock Holding History

Cerity Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.2K Buy
+38,014
New +$68K ﹤0.01% 3247

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners's IKT Position: Q2 2026 in Review

Cerity Partners opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 38,014 shares worth $77.2K. The stake represents ﹤0.01% of the portfolio and ranks #3247 among its holdings.

106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Cerity Partners held 38,014 shares of Inhibikase Therapeutics worth $77.2K as of Q2 2026.
  • Inhibikase Therapeutics was a new Cerity Partners position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3247 holding.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.